Company intelligence / Profile preview
EMD Serono
Rockland, Massachusetts, United Statesemdserono.com ↗
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Commercial
01
Overview
EMD Serono has multiple commercial products and an expanding pipeline in neurology, oncology, immuno-oncology and immunology. Recent clinical developments include advancing M9140 (anti-CEACAM5 ADC) to Phase Ib in colorectal cancer, with plans to expand to other CEACAM5-expressing tumors, and preparing to enter first-in-human studies with M3554 (anti-GD2 ADC) in 2024.[9]
- Therapeutic areas
- Women's HealthOncologyNeurology
- Modalities
- Small moleculesbiologicsantibody-drug conjugates (ADCs)
- Industry
- Pharma
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on EMD Serono.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMD Serono.